PMID: 42165732

Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.

Gupta Monika, Shukla Jitendra

The Indian journal of medical research · 2026

Vol. 163, Issue 4, pp. 427-435

View on PubMedDOI

This entry links to third-party literature. For research use only.

HumansIncretinsDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1SemaglutideTirzepatideObesityDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptides

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.